▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #121 by analyst upside · 2026-06-27
ALLR
Allarity Therapeutics, Inc.
Healthcare · Market Cap $21M · P/E 0x
ANALYST PRICE TARGET
+688.5%
implied upside to consensus target
Current Price $1.3
Consensus Target $10.25
Bull Target $10.25
Bear Target $10.25
Analysts Covering 1
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
0
Sell
0
52-Week Low $0.77
52-Week High $2.35
YTD Return +14.0%
FUNDAMENTALS
Market Cap $21M
P/E Ratio (TTM) N/A
Forward P/E -1.3x
EPS (TTM) $-0.70
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.77
52-Week High $2.35
Current Price $1.3
Bear Target $10.25
Bull Target $10.25
● Now $1.3 ● Target $10.25
TRADING DATA
Avg Volume 193K
YTD Return +14.0%
Analyst Count 1
Consensus Buy
Upside to Target +688.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Allarity Therapeutics, Inc. (ALLR) is currently trading at $1.3 with a Wall Street consensus price target of $10.25, implying potential upside of 688.5% over the next 12 months. 1 analysts currently cover ALLR, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $10.25, while the most cautious has a target of $10.25.

ALLR operates in the Healthcare sector with a market capitalisation of $21M. The stock is up 14.0% year-to-date and is currently trading near the lower end of its 52-week range of $0.77 – $2.35.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PSTV +757.1%
Plus Therapeutics, Inc.
$29M · P/E 0.2x · Buy
DWTX +748.5%
Dogwood Therapeutics, Inc.
$55M · P/E 1.4x · Strong Buy
ETST +566.7%
Earth Science Tech, Inc.
$43M · P/E 15.0x · Hold
VXRT +488.2%
Vaxart, Inc.
$123M · P/E 3.2x · Buy
AGEN +411.6%
Agenus Inc.
$126M · P/E 1.4x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ALLR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Ascendiant Capital — Reiterated
Buy → Buy 2026-06-08 Building track record
Ascendiant Capital — Reiterated
Buy → Buy 2026-04-10 Building track record
Ascendiant Capital — Reiterated
Buy → Buy 2025-12-09 Building track record
Ascendiant Capital ● Initiated
Buy 2025-07-28 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →